Navigation Links
Low-Dose Steroid Combined With Lenalidomide Prolongs Survival,Compared With High-Dose Steroid for Multiple Myeloma Treatment

d lenalidomide and dexamethasone given at standard doses. The second group received standard-dose lenalidomide and low-dose dexamethasone. The primary objective was to determine if the low-dose arm would have similar response rates and lower toxicity than the standard-dose arm.

Randomized trials are the gold standard for evaluation of the effectiveness of new treatments, said NCI Director John E. Niederhuber, M.D. These results also emphasize once again the importance of NCIs rigorous program of oversight, which brings highly qualified clinician scientists to serve as members of data safety and monitoring committees.

Lenalidomide, a derivative of thalidomide, was approved by the U.S. Food and Drug Administration in 2006 to be used in combination with dexamethasone for the treatment of multiple myeloma in patients who received at least one prior therapy for their disease. Dexamethasone is a steroid that acts as an anti-inflammatory and as an immunosuppressant and has numerous uses in medical practice.

ECOG has a long history in developing new treatments for multiple myeloma, according to Robert L. Comis, M.D., ECOG group chairperson. The application of this effective and less toxic approach will benefit many patients with this disease.

Celgene, Inc., Summit, N.J., which manufactures lenalidomide, provided lenalidomide for the trial under a Cooperative Research and Development Agreement with NCI for the clinical development of lenalidomide.

Multiple myeloma is a cancer of plasma cells that are found in blood and bone marrow. In 2007, an estimated 19,900 people in the United States will be diagnosed with multiple myeloma and an estimated 10,790 people will die of the disease.

For more information about multiple myeloma, visit the NCI website at http://myeloma.cancer.gov.

For more information about cancer, please visit the NCI website at




Page: 1 2 3

Related medicine technology :

1. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
2. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
3. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
4. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
5. Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer
6. Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients
7. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
8. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
9. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
10. Gentiums Defibrotide Seen as Active in Multiple Myeloma
11. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model

Post Your Comments:
(Date:12/2/2009)...re/ -- Reportlinker.com announces that a new marke..., Electrodes for Medical Devices - A Global Ma...om/p0164320/Electrodes-for-Medical-Devices---A-Glo...lectronic devices detect electrical signals in pat...chemical reactions. Medical application areas incl...
(Date:12/2/2009)...ire/ -- Reportlinker.com announces that a new mark...,, Chiral Technology - International Technolog...ker.com/p0164212/Chiral-Technology---International...eveloping small molecule chiral technology sector ...ical companies adding chiral expertise to their po...
(Date:12/2/2009)...re/ -- Reportlinker.com announces that a new marke..., Global Markets for Asthma and COPD Drugs ...-Markets-for-Asthma-and-COPD-Drugs.html ,, Pro...r medications that treat asthma and chronic obstru...et forecasts through 2014 for medications that tre...
Breaking Medicine Technology:Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 2Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 3Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 4Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 5Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 6Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 7Reportlinker Adds Chiral Technology - International Technology & Market Trends 2Reportlinker Adds Chiral Technology - International Technology & Market Trends 3Reportlinker Adds Chiral Technology - International Technology & Market Trends 4Reportlinker Adds Chiral Technology - International Technology & Market Trends 5Reportlinker Adds Global Markets for Asthma and COPD Drugs 2Reportlinker Adds Global Markets for Asthma and COPD Drugs 3Reportlinker Adds Global Markets for Asthma and COPD Drugs 4Reportlinker Adds Global Markets for Asthma and COPD Drugs 5Reportlinker Adds Global Markets for Asthma and COPD Drugs 6Reportlinker Adds Global Markets for Asthma and COPD Drugs 7Reportlinker Adds Global Markets for Asthma and COPD Drugs 8Reportlinker Adds Global Markets for Asthma and COPD Drugs 9Reportlinker Adds Global Markets for Asthma and COPD Drugs 10Reportlinker Adds Global Markets for Asthma and COPD Drugs 11MoxDuo 28TM 29 IR Demonstrates Fewer Side Effects Than Percocet 28R 29 4901 1MoxDuo 28TM 29 IR Demonstrates Fewer Side Effects Than Percocet 28R 29 4901 2MoxDuo 28TM 29 IR Demonstrates Fewer Side Effects Than Percocet 28R 29 4901 3MoxDuo 28TM 29 IR Demonstrates Fewer Side Effects Than Percocet 28R 29 4901 4A better test to detect DNA for diagnosing diease investigating crimes 55405 1New tools for sustainable farming 9703 1New tools for sustainable farming 9703 2New tools for sustainable farming 9703 3
...mber 24 BioView Ltd,(TASE: BIOV) from Rehovot, Is...cal trial of the non-invasive diagnostic test unde... In the trial a total of 76 sputum samples were c...hy individuals that never smoked 2. Heavy smokers... cancer patients (Stage 1) 4. Advanced stage lung...
...3 Clinical Program Initiated -, CAMBRIDGE, Mass. ...formerly Microbia) and Forest Laboratories, Inc.,(...ults of a Phase 2b study,investigating linaclotide...ble bowel syndrome with constipation (IBS-C) in a ...nterology (ACG) 2008 Annual Scientific,Meeting in ...
Other Medicine Technology:BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test 2Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference 2Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference 3Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference 4Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference 5
(Date:12/3/2009)... Kessock receives President’s Service Award....mber 2, 2009 -- CS3 Technology, a leading professi...ons to businesses across the country, is pleased t...year at their company-wide retreat, CS3 recognizes...his year, Cindi Kessock earned the President&rsquo...
(Date:12/3/2009)...olutionary device that allows people to sanitize t... (PRWEB) December 3, 2009 ... and magazine covers day after day -- dire statist... influenza A (swine flu) . Reports of vaccine sho...ging picture during this pandemic. , ,But finally...
(Date:12/3/2009)...tobacco has been the life-long focus of his resear...the Lombardi Comprehensive Cancer Center at George... to edit a special-edition of Cancer Epidemiology...est research practices in tobacco science from res... CEBP , a journal of the American Association for...
(Date:12/2/2009)...c. 2 Reportlinker.com announces th...s catalogue: ,, Kinase Inhibitors: Global Mar...9/Kinase-Inhibitors-Global-Markets.html ,, F... the years 2005 through 2008, and projections for ...) through 2014 ,, An overview of the market fo...
(Date:12/2/2009)...PRNewswire-USNewswire/ -- ,, Statement by John... Association ,, In response to a new campaign...ADA) to educate consumers and rid the marketplace ...upplements, the Natural Products Association, the ...retailers and manufacturers of dietary supplements...
Breaking Medicine News(10 mins):Health News:CS3 Technology Announces Annual Employee Awards 2Health News:CS3 Technology Announces Annual Employee Awards 3Health News:Finally, Some Good News about Swine Flu 2Health News:Lombardi's Shields leads special journal focused on tobacco research 2Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 2Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 3Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 4Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 5Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 6Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 7Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 8Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 9Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 10Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 11Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 12Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 13Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 14Health News:Reportlinker Adds Kinase Inhibitors: Global Markets 15Health News:Natural Products Association Issues Statement on New Supplement Safety Campaign 2
...ber 8 NeurogesX, Inc.,(Nasdaq: NGSX ), a biophar...rcializing novel pain management therapies, today ...rter of 2007 on Wednesday, November 14,2007, after...ony DiTonno,President and Chief Executive Officer,...
...ugs is top risk factor for injury, study finds , T... with osteoporosis stick to their medications may ...report. , When an osteoporosis patient suffers a f...nts are hip, spine, and wrist fractures. , This n...
...ed shoulder pain caused by osteoarthritis , ...ems to relieve shoulder pain in arthritis sufferer...d people start using it until we have the definiti...ts needed to be assessed before the treatment coul...
...g on his experience as a physician in a small medi... MD, FACP, president-elect of the American College...use Small Business Committee Subcommittee on Regul... played on our practice, noted Dr. Harris. These ...
...covered that a molecular switch in the protein mak...t common forms of lethal breast cancer worldwide. ...cine could lead to new therapies for the cancer, c...ng women in developing countries, and 30 percent o...
...8, 2007) Virginia Commonwealth University researc...y enzymes that play a major role in clotting disor... clots in the lungs and those localized deep in th...ering blood unable to clot effectively. These diso...
Other Medicine News:Health News:NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007 2Health News:NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007 3Health News:Sticking With Meds Lowers Elderly Fracture Risk 2Health News:Botox Offers Shot in Arm for Arthritis Sufferers 2Health News:Looming Medicare cuts will disproportionately hurt physicians in small practices 2Health News:A molecular switch is linked to a common breast cancer 2Health News:Researchers identify molecules with interesting anti-clotting properties 2
...rade; Shoulder Orthosis Until now, laborious custo... splint. Adjustability was limited and modificatio..., difficult and cumbersome.,The GunSlinger evolve...jor Boston teaching hospital. This orthosis can be...
Generation II Shoulder Abduction System
...able pre-fabricated orthosis is designed for the m...physeal fractures. The lightweight anatomical desi...sue compression for optimal control of humeral seg...the shoulder and elbow joints. It is formed of a s...
Humeral Splint
Medicine Products: